Cite
Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients.
MLA
Monneret, Guillaume, et al. “Monitoring Monocyte HLA-DR Expression and CD4 + T Lymphocyte Count in Dexamethasone-Treated Severe COVID-19 Patients.” Annals of Intensive Care, vol. 14, no. 1, May 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s13613-024-01310-5.
APA
Monneret, G., Voirin, N., Richard, J.-C., Cour, M., Rimmelé, T., Garnier, L., Yonis, H., Coudereau, R., Gossez, M., Malcus, C., Wallet, F., Delignette, M.-C., Dailler, F., Buisson, M., Argaud, L., Lukaszewicz, A.-C., Venet, F., Pescarmona, R., Lombard, C., & Perret, M. (2024). Monitoring monocyte HLA-DR expression and CD4 + T lymphocyte count in dexamethasone-treated severe COVID-19 patients. Annals of Intensive Care, 14(1), 1–12. https://doi.org/10.1186/s13613-024-01310-5
Chicago
Monneret, Guillaume, Nicolas Voirin, Jean-Christophe Richard, Martin Cour, Thomas Rimmelé, Lorna Garnier, Hodane Yonis, et al. 2024. “Monitoring Monocyte HLA-DR Expression and CD4 + T Lymphocyte Count in Dexamethasone-Treated Severe COVID-19 Patients.” Annals of Intensive Care 14 (1): 1–12. doi:10.1186/s13613-024-01310-5.